RZLT insider transaction filings
Rezolute, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-03. Screen RZLT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Elam Nevan C — CEO, Director | 1 | — | — | 1 |
| Evans Daron — CFO | 1 | — | — | 1 |
| Karnawat Sunil Ratilal — Chief Commercial Officer | 1 | — | — | 1 |
| ROBERTS BRIAN KENNETH — Chief Medical Officer | 1 | — | — | 1 |
Recent Form 4 filings — Rezolute, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Tax withholding (F): 2,267 @ $4.50 | EDGAR |
| 2026-07-07 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Tax withholding (F): 3,062 @ $4.99 | EDGAR |
| 2026-07-07 | 4 | Evans Daron — CFO | Tax withholding (F): 3,062 @ $4.99 | EDGAR |
| 2026-07-07 | 4 | Elam Nevan C — CEO, Director | Tax withholding (F): 8,004 @ $4.99 | EDGAR |
| 2026-03-31 | 4 | Evans Daron — CFO | Purchase (P): 10,000 @ $2.85 | EDGAR |
| 2026-03-04 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Tax withholding (F): 11,439 @ $2.99 | EDGAR |
| 2026-03-04 | 4 | Evans Daron — CFO | Tax withholding (F): 11,438 @ $2.99 | EDGAR |
| 2026-03-04 | 4 | Elam Nevan C — CEO, Director | Tax withholding (F): 27,618 @ $2.99 | EDGAR |
| 2025-12-17 | 4 | Hogenhuis Wladimir — Director | Purchase (P): 5,650 @ $1.69 | EDGAR |
| 2025-12-17 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Purchase (P): 28,000 @ $1.70 | EDGAR |
| 2025-12-15 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Purchase (P): 12,000 @ $1.62 · Purchase (P): 100 @ $1.60 | EDGAR |
| 2025-12-15 | 4 | Evans Daron — CFO | Purchase (P): 40,000 @ $1.77 · Purchase (P): 2,500 @ $1.78 · Purchase (P): 2,500 @ $1.79 | EDGAR |
| 2025-12-15 | 4 | Elam Nevan C — CEO, Director | Purchase (P): 32,000 @ $1.59 | EDGAR |
| 2025-11-21 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Grant/award (A): 123,000 @ $0 · Code (?): 72,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Grant/award (A): 32,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | KREHER NERISSA — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Hogenhuis Wladimir — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Harris Erik — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Kim Young-Jin — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | FAUCHET PHILIPPE — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Evans Daron — CFO | Grant/award (A): 107,000 @ $0 · Grant/award (A): 63,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Labrucherie Gil M — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Elam Nevan C — CEO, Director | Grant/award (A): 317,000 @ $0 · Grant/award (A): 186,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | Karnawat Sunil Ratilal — Chief Commercial Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Purchase (P): 2,500 @ $4.38 | EDGAR |
| 2025-06-24 | 4 | Evans Daron — CFO | Purchase (P): 5,000 @ $4.05 | EDGAR |
| 2025-06-23 | 4 | Kim Young-Jin — Director | Purchase (P): 1,230,769 @ $3.25 | EDGAR |
| 2025-06-23 | 4 | KREHER NERISSA — Director | Purchase (P): 3,076 @ $3.25 | EDGAR |
| 2025-06-13 | 4 | KREHER NERISSA — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Hogenhuis Wladimir — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Labrucherie Gil M — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Kim Young-Jin — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | FAUCHET PHILIPPE — Director | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Grant/award (A): 26,000 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Evans Daron — CFO | Grant/award (A): 26,000 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Elam Nevan C — CEO, Director | Grant/award (A): 68,000 @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Hogenhuis Wladimir — Director | Purchase (P): 6,758 @ $2.92 | EDGAR |
| 2025-03-31 | 4 | Elam Nevan C — CEO, Director | Purchase (P): 12,302 @ $2.85 | EDGAR |
| 2025-03-28 | 4 | Evans Daron — CFO | Purchase (P): 10,000 @ $2.89 · Purchase (P): 10,000 @ $2.88 | EDGAR |
| 2025-03-26 | 4 | Harris Erik — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Hogenhuis Wladimir — Director | Grant/award (A): 25,500 @ $0 · Purchase (P): 10,000 @ $4.70 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Labrucherie Gil M — Director | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | KREHER NERISSA — Director | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Kim Young-Jin — Director | Grant/award (A): 25,500 @ $0 · Purchase (P): 1,250,000 @ $4 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | ROBERTS BRIAN KENNETH — Chief Medical Officer | Grant/award (A): 77,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | FAUCHET PHILIPPE — Director | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Evans Daron — CFO | Grant/award (A): 77,000 @ $0 · Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Elam Nevan C — CEO, Director | Grant/award (A): 204,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Evans Daron — CFO | Purchase (P): 10,000 @ $4.29 | EDGAR |
| 2024-12-12 | 4 | Evans Daron — CFO | Purchase (P): 9,000 @ $4.60 | EDGAR |
Recent 8-K events — Rezolute, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-06-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RZLT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →